Peficitinib Application Scope

Peficitinib is an oral Janus kinase (JAK) inhibitor used primarily for the treatment of rheumatoid arthritis (RA), particularly in patients who have had an inadequate response to conventional therapies.

By inhibiting JAK enzymes, peficitinib disrupts the signaling pathways that contribute to the inflammatory processes characteristic of RA.

Peficitinib

Characteristics of Peficitinib

Ingredients: The active ingredient is peficitinib hydrobromide.
Properties: Peficitinib is a small-molecule inhibitor targeting JAK1, JAK2, JAK3, and tyrosine kinase 2, thereby modulating immune responses involved in RA.
Specification: Available in tablet form with strengths of 50 mg and 100 mg.
Packaging Specification: Supplied in blister packs containing 50 mg or 100 mg tablets.
Storage: Store in a cool, dry place away from direct sunlight.
Expiry Date: Refer to the packaging for the specific expiration date.
Executive Standard: Approved by the Japanese Ministry of Health, Labour and Welfare.
Approval Number: Specific approval numbers are provided on the product labeling.
Date of Revision: Check the prescribing information for the latest revision date.
Manufacturer: Astellas Pharma Inc.

Guidelines for the Use of Peficitinib

Dosage and Administration: The recommended dose is 150 mg orally once daily after a meal. Depending on the patient’s condition, the dose may be reduced to 100 mg once daily.
Adverse Reactions: Common side effects include upper respiratory tract infections, nasopharyngitis, and elevated liver enzymes. Serious adverse reactions may include infections and gastrointestinal perforations.
Contraindications: Patients with known hypersensitivity to Astellas or any of its components should not use this medication.
Precautions: Caution is advised in patients with a history of chronic infections, liver dysfunction, or those at risk for gastrointestinal perforation. Regular monitoring of blood counts and liver enzymes is recommended.

Peficitinib Interactions

Drug Interactions: Concomitant use with other JAK inhibitors or biologic disease-modifying antirheumatic drugs (DMARDs) is not recommended due to an increased risk of adverse effects.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.